IMNM Immunome, Inc.
USHealthcareAs of 2026-08-24
Why IMNM matters now
Immunome, Inc. (IMNM) is a US stock in Healthcare. The latest InvestLog snapshot shows $28.01 with -1.79% on the session and $2.68B in market capitalization; recent performance reads 1-month -4.68% and YTD -12.76%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-53.8M, and EPS of $-0.48. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -11.5%.
The latest indexable market news headline is "argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing" from MarketBeat.
Additional event context on this page matters because analyst consensus is Buy with a median target of $36.50; recent insider activity includes Rosett Max filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.60
P/S
446.19
EV/EBITDA
-5.47
DCF Value
$7.38
FCF Yield
-11.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1161.9%
Operating Margin
-5947.9%
Net Margin
-5593.8%
ROE
-51.2%
ROA
-36.2%
ROIC
-40.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-53.8M | $-0.48 |
| Q4 2025 | $0.00 | $-69.9M | $-0.76 |
| FY 2025 | $6.9M | $-212.4M | $-2.43 |
| Q3 2025 | $0.00 | $-57.5M | $-0.65 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$36.50
Target (Median)
$36.50
Target Range
$33.00 - $40.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.07
Immunome, Inc. functions as a biopharmaceutical company dedicated to the discovery and advancement of antibody-based therapies for both cancer and infectious illnesses. A pivotal project in its oncology portfolio is IMM-ONC-01, which is engineered to target the IL-38 immune checkpoint – a protein originating from tumors that enables cancer cells to bypass the body's immune surveillance. Additionally, the company is developing IMM-BCP-01, an experimental antibody cocktail designed for the management of SARS-CoV-2 infections and COVID-19. This enterprise was founded in 2006 and its principal operations are based in Exton, Pennsylvania.